Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Astrazeneca (AZN) through the VizualStocks API.
AstraZeneca’s profit shares, revenue shares and royalties linked to sales booked by collaboration partners. The series uses the separate Alliance Revenue presentation introduced in 2023, including explicitly recast 2022 comparisons.
allianceRevenueUpfront licensing amounts and event-triggered milestones from collaborations in which AstraZeneca retains a significant ongoing economic interest. This series excludes recurring partner-sales income classified as Alliance Revenue under the presentation introduced in 2023.
collaborationRevenueTotal Revenue from AstraZeneca’s cardiovascular, renal and metabolism medicines, including Farxiga, Brilinta, Crestor and Lokelma. History starts with the issuer’s 2022 therapy-area scope and includes applicable alliance and collaboration income.
cvrmRevenueAstraZeneca Total Revenue attributed to its Emerging Markets region, including China and the other emerging markets presented in its results announcements. It includes all revenue types and is broader than the China-only disclosure.
emergingMarketsRevenueAstraZeneca Total Revenue attributed to its Established Rest of World region, covering Japan, Canada, Australia and New Zealand. It includes all revenue types attributed to this region in the results announcements.
establishedRestOfWorldRevenueAstraZeneca Total Revenue attributed to Europe in its recurring regional commercial performance table. It includes Product Sales, Alliance Revenue and Collaboration Revenue attributed to the region.
europeRevenueTotal Revenue from AstraZeneca’s infectious-disease medicines, including vaccines and immune therapies such as Beyfortus and FluMist. This therapy area was called Vaccines and Immune Therapies through 2025 and was renamed Infectious Disease in 2026.
infectiousDiseaseRevenueTotal Revenue from AstraZeneca’s cancer medicines, including product sales and applicable alliance and collaboration income. History starts in 2022 after Koselugo moved to Rare Disease.
oncologyRevenueTotal Revenue from medicines that AstraZeneca groups outside its named Oncology, BioPharmaceuticals and Rare Disease therapy areas. This is the issuer’s reported Other Medicines category under its 2022 onward therapy-area structure.
otherMedicinesRevenueRevenue from medicines for which AstraZeneca acts as principal and records sales to the customer. It excludes profit shares and royalties reported as Alliance Revenue and licensing amounts reported as Collaboration Revenue.
productSalesTotal Revenue from AstraZeneca’s rare-disease medicines, including Ultomiris, Soliris, Strensiq and Koselugo. History starts in 2022 when Koselugo moved into this therapy area and Andexxa moved out to Cardiovascular, Renal and Metabolism.
rareDiseaseRevenueTotal Revenue from AstraZeneca’s respiratory and immunology medicines, including Symbicort, Fasenra, Breztri, Tezspire and Saphnelo. It includes product sales and applicable alliance and collaboration income.
respiratoryAndImmunologyRevenueAstraZeneca Total Revenue attributed to the United States in its recurring regional commercial performance table. It includes Product Sales, Alliance Revenue and Collaboration Revenue attributed to the region.
usRevenue